# AC-CHOP Versus CHOP in Patients With Previously Untreated PTCL-TFH

> **NCT05678933** · PHASE3 · ENROLLING_BY_INVITATION · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 200 (estimated)

## Conditions studied

- Peripheral T-cell Lymphoma Targeted Therapy

## Interventions

- **DRUG:** Azacitidine
- **DRUG:** Chidamide
- **DRUG:** Cyclophosphamide
- **DRUG:** Epirubicin
- **DRUG:** Vincristine
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT05678933
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2023-01-01
- **Primary completion:** 2027-12-01
- **Final completion:** 2029-12-01
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2023-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05678933

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05678933, "AC-CHOP Versus CHOP in Patients With Previously Untreated PTCL-TFH". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05678933. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*